{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:24:22Z","timestamp":1788279862599,"version":"build-2803163510"},"reference-count":64,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T00:00:00Z","timestamp":1727568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>Juvenile idiopathic arthritis (JIA) is the most prevalent pediatric rheumatic disease. While disease\u2010modifying antirheumatic drugs (DMARDs), especially biologics, have greatly transformed the management of JIA, there remain some unmet medical needs that require new treatment options. The objective of this work was to describe and apply a modeling and simulation approach to extrapolate upadacitinib efficacy from the adult diseases, rheumatoid arthritis (RA) and psoriatic arthritis (PsA), to their respective pediatric diseases, polyarticular course JIA (pcJIA), and juvenile PsA (JPsA). A population pharmacokinetic model characterized upadacitinib pharmacokinetics in pediatric patients using data from two phase I studies in pediatric patients with pcJIA (<jats:italic>N<\/jats:italic>\u2009=\u200951) or atopic dermatitis (<jats:italic>N<\/jats:italic>\u2009=\u200933). Efficacy simulations were conducted using previously developed exposure\u2013response models in adults with RA and PsA. Real\u2010world pcJIA and JPsA patient databases were leveraged to construct representative patient profiles for the targeted population. Following administration of the proposed weight\u2010based dosing regimen, the model\u2010predicted median upadacitinib plasma exposures in pediatric patients were within 20% of those in adult RA and PsA patients receiving the approved adult regimen. Simulations demonstrate that upadacitinib efficacy in pcJIA and JPsA is predicted to be non\u2010inferior to that in adults with RA or PsA, respectively. The results of this work enabled recent approvals of upadacitinib for the treatment of polyarticular JIA and JPsA in the United States. Upadacitinib safety in pediatrics is being further evaluated in ongoing clinical trials.<\/jats:p>","DOI":"10.1002\/cpt.3441","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T05:43:42Z","timestamp":1727675022000},"page":"1635-1645","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure\u2013Response Models, and Real\u2010World Patient Data"],"prefix":"10.1002","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8986-2189","authenticated-orcid":false,"given":"Yuli","family":"Qian","sequence":"first","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5822-4246","authenticated-orcid":false,"given":"Louisa","family":"Schlachter","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Deutschland GmbH &amp; Co. KG  Ludwigshafen am Rhein Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5946-2364","authenticated-orcid":false,"given":"Doerthe","family":"Eckert","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Deutschland GmbH &amp; Co. KG  Ludwigshafen am Rhein Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7986-4447","authenticated-orcid":false,"given":"Sven","family":"Stodtmann","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Deutschland GmbH &amp; Co. KG  Ludwigshafen am Rhein Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1945-9255","authenticated-orcid":false,"given":"Anna","family":"Shmagel","sequence":"additional","affiliation":[{"name":"Immunology Development AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1593-8336","authenticated-orcid":false,"given":"Yi","family":"Peng","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4444-1230","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0959-2025","authenticated-orcid":false,"given":"Mohamed\u2010Eslam F.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,29]]},"reference":[{"key":"e_1_2_9_1_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23870"},{"key":"e_1_2_9_2_1","first-page":"1520","article-title":"Worldwide prevalence of juvenile arthritis why does it vary so much?","volume":"29","author":"Manners P.J.","year":"2002","journal-title":"J. Rheumatol."},{"key":"e_1_2_9_3_1","first-page":"390","article-title":"International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty R.E.","year":"2004","journal-title":"J. Rheumatol."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel218"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.13.1671"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10986"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401219"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41390"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23853"},{"key":"e_1_2_9_10_1","unstructured":"AbbVie Inc.Rinvoq (upadacitinib) [package insert]. U.S. Food and Drug Administration <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218347s000lbl.pdf> (2024). Accessed June 24 2024."},{"key":"e_1_2_9_11_1","unstructured":"AbbVie Inc.Summary of product characteristics: RINVOQ 15 mg 30 mg 45 mg prolonged\u2010release tablets (Great Britain). In: Electronic Medicines Compendium (EMC). Last updated May 16 2024. <https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/rinvoq\u2010epar\u2010product\u2010information_en.pdf>. Accessed July 10 2024."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"e_1_2_9_16_1","unstructured":"ICH E11A Draft Guidance on Pediatric Extrapolation.2022. <https:\/\/database.ich.org\/sites\/default\/files\/ICH_E11A_Document_Step2_Guideline_2022_0404_0.pdf>. Accessed March 8 2024."},{"key":"e_1_2_9_17_1","unstructured":"ICH E11A Expert Working Group.ICH E11A Pediatric Extrapolation. Pediatric Extrapolation Case Example: Development of a hypothetical TNF\u2010alpha inhibitor \u201cDrug X\u201d for the treatment of polyarticular juvenile idiopathic arthritis (pJIA).2022. <https:\/\/database.ich.org\/sites\/default\/files\/ICH_E11A_TrainingMaterial_CaseExample_2022_0701.pdf>. Accessed July 10 2024."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/berh.2002.0233"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.141234"},{"key":"e_1_2_9_21_1","first-page":"579","article-title":"Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year follow up","volume":"30","author":"Fantini F.","year":"2003","journal-title":"J. Rheumatol."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780341209"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.148635"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00918651"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27447"},{"key":"e_1_2_9_26_1","first-page":"1349","article-title":"Elevated concentrations of monocyte derived cytokines in synovial fluid of children with enthesitis related arthritis and polyarticular types of juvenile idiopathic arthritis","volume":"32","author":"Saxena N.","year":"2005","journal-title":"J. Rheumatol."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210456"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23940"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep122"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10710"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706290"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00004"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60453-5"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2218"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-017-0212-y"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01255-1"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00921-2"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222849"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150430"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"e_1_2_9_43_1","first-page":"166","article-title":"Juvenile psoriatic arthritis: followup and evaluation of diagnostic criteria","volume":"23","author":"Roberton D.M.","year":"1996","journal-title":"J. Rheumatol."},{"key":"e_1_2_9_44_1","first-page":"108","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor W.","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"e_1_2_9_45_1","unstructured":"U.S. Food and Drug Administration.NDA 211675\/S\u2010021 and S\u2010022. April 26 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2024\/211675Orig1s021 %20s022ltr.pdf. Accessed September 18 2024."},{"key":"e_1_2_9_46_1","first-page":"666","article-title":"Pharmacokinetics of upadacitinib in pediatric patients with polyarticular course juvenile idiopathic arthritis","volume":"82","author":"Qian Y.","year":"2023","journal-title":"Ann. Rheum. Dis"},{"key":"e_1_2_9_47_1","article-title":"Pharmacokinetics, safety, tolerability, and exploratory efficacy of Upadacitinib in children with severe atopic dermatitis","author":"Qian Y.","year":"2024","journal-title":"Clin. Ther."},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1550"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00739-3"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0419-y"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2236"},{"key":"e_1_2_9_52_1","unstructured":"Centers for Disease Control and Prevention National Center for Health Statistics.CDC Growth Charts. <https:\/\/www.cdc.gov\/growthcharts\/data_tables.htm>. Accessed July 2023."},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13146"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1671"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41032"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.576"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1177\/17407745221132302"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400703"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360601"},{"key":"e_1_2_9_62_1","unstructured":"FDA Center for Drug Evaluation and Research.General clinical pharmacology considerations for pediatric studies of drugs including biological products. Including Biological Products.2022. <https:\/\/www.fda.gov\/media\/90358\/download>. Accessed March 2024."},{"key":"e_1_2_9_63_1","unstructured":"European Medicines Agency.Reflection paper on the use of extrapolation in the development of medicines for paediatricsOctober 7 2018. <https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/adopted\u2010reflection\u2010paper\u2010use\u2010extrapolation\u2010development\u2010medicines\u2010paediatrics\u2010revision\u20101_en.pdf>. Accessed June 2024."},{"key":"e_1_2_9_64_1","unstructured":"European Medicines Agency.Decision Letter P\/0510\/2021. December 3 2021. <https:\/\/www.ema.europa.eu\/en\/documents\/pip\u2010decision\/p05102021\u2010ema\u2010decision\u20103\u2010december\u20102021\u2010acceptance\u2010modification\u2010agreed\u2010paediatric\u2010investigation\u2010plan\u2010upadacitinib\u2010rinvoq\u2010emea\u2010001741\u2010pip01\u201014\u2010m05_en.pdf>. Accessed July 10 2024."}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T06:23:09Z","timestamp":1731651789000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,29]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/cpt.3441"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3441","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,29]]},"assertion":[{"value":"2024-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}